Premium
Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder
Author(s) -
Pavlotsky Abraham,
Eidelman Abraham,
Barak Frida,
Alon Haim,
Horn Yoav
Publication year - 1989
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930410106
Subject(s) - medicine , cystoscopy , mitomycin c , transitional cell carcinoma , urology , chemotherapy , urinary bladder , carcinoma , resection , urinary system , surgery , bladder cancer , cancer
We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.